ASX 200 Healthcare Giants: Performance Snapshot of CSL, SIG, PME, RMD, and FPH

3 min read | May 26, 2025 05:26 PM AEST | By Team Kalkine Media

Google News:

ASX 200 Healthcare Giants: Performance Snapshot of CSL, SIG, PME, RMD, and FPH — Image source: Shutterstock

Recent News

Zip Shares Push Higher as Market Watches Key Turning Point

Could These Under-the-Radar ASX Stocks Be Worth Watching?

ASX 200 Soars as Trump Signals Surprise Iran Peace Shift

Which ASX Small Caps Are Making Early Moves Today?

Make Kalkine Media
My Trusted Source

Highlights

CSL (ASX:CSL) shows modest gains while maintaining its leadership in biopharmaceuticals

SIG (ASX:SIG) continues to lead pharmacy distribution despite a slight decline

PME (ASX:PME) and RMD (ASX:RMD) experience minor pullbacks amid strong annual trends

Australia’s healthcare sector, a key component of the ASX 200 index, showcases a wide array of companies with strong international influence. On 26 May 2025, several of the sector’s top names—CSL Limited (ASX:CSL), Sigma Healthcare (ASX:SIG), Pro Medicus (ASX:PME), ResMed (ASX:RMD), and Fisher & Paykel Healthcare (ASX:FPH)—displayed mixed trading outcomes, reflecting both market dynamics and company-specific developments.

CSL Limited (ASX:CSL): Global Biotech Pillar Sees Mild Upside

CSL, ranked among the largest companies on the ASX 200, posted a minor gain by midday. Known for its broad biopharmaceutical offerings, CSL has a significant footprint in plasma-derived therapies and influenza vaccines. Despite recent downward pressure year-to-date, the company remains a foundational part of Australia’s healthcare landscape due to its consistent product demand and international operations.

Sigma Healthcare Ltd (ASX:SIG): Distribution Leader Experiences a Pause

Sigma Healthcare, a major distributor in the pharmaceutical supply chain, showed a slight decline on the day. Its strong yearly growth has been driven by structural healthcare reforms and enhanced access to pharmaceutical services. SIG continues to maintain high trading volume and has been among the most active performers in the healthcare sector of the ASX 200, benefiting from sectoral momentum and operational scalability.

Pro Medicus Ltd (ASX:PME): Imaging Innovator Pulls Back After Strong Run

Pro Medicus, a trailblazer in imaging software and radiology solutions, experienced a marginal decline following a period of notable upward movement. With robust international contracts and rising demand for digital diagnostics, PME has seen substantial appreciation over the past months. The company’s consistent technological advancement supports its presence among top-tier healthcare names on the ASX 200.

ResMed Inc (ASX:RMD): Respiratory Device Leader Trades Softer

ResMed, with its focus on sleep and respiratory care technologies, registered one of the more significant declines in the sector during the session. Despite the day’s lower trade, RMD maintains a solid track record over the past year. Its reach across more than one hundred countries and the integration of cloud-connected health systems underpin its influence in the medtech landscape on the ASX 200.

Fisher & Paykel Healthcare (ASX:FPH): Steady Growth in Respiratory Segment

Fisher & Paykel Healthcare, a specialist in respiratory and sleep therapy devices, saw a minor upward move during the session. Its consistent growth has been supported by demand from hospitals globally. FPH maintains strong sales across numerous markets and continues to invest in product development, reinforcing its sector rank within the ASX 200.

ASX 200 Healthcare Sector Sees Mixed Intraday Momentum

The trading session revealed varied performances among leading healthcare players. Some names gained ground, while others faced pullbacks after recent rallies. The sector remains defined by diverse business models—ranging from biotech and medtech to pharmaceutical logistics—each navigating macroeconomic conditions and innovation-led growth trajectories.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.